November 2, 2021 -- Nautilus Biotechnology and Abcam have signed a strategic development and supply partnership agreement.
Under the new partnership, Abcam will provide its recombinant monoclonal antibody development technologies and expertise to enhance Nautilus' reagent research and development activities, according to the companies. A long-term supply relationship has also been established.
Initially, the partnership will focus on the collaborative development of affinity binding reagents for use on the Nautilus proteomic analysis system. The relationship will expand to large-scale manufacturing and the supply of reagents for commercialization, the companies said.